B. Riley analyst Mayank Mamtani kept a Buy rating on Kymera Therapeutics (KYMR) with a $60 price target following a transfer of coverage. The firm says investor enthusiasm appears to be building for KT-621’s Phase 1b atopic dermatitis patient data update in Q4. Riley is “encouraged” by the “impressive” safety profile already demonstrated at high doses.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Is KYMR a Buy, Before Earnings?
- Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
- Gilead estimates Q2 acquired IPR&D expenses of $61M
- Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
- Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships